Amicus Therapeutics Inc. (FOLD) Performance and Fundamentals Dashboard tells a completely different story

Amicus Therapeutics Inc. (NASDAQ: FOLD) stock jumped 4.12% on Friday to $10.37 against a previous-day closing price of $9.96. With 2.57 million shares changed hands, the volume of the stock remained lighter than its average volume of 3.72 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $10.43 whereas the lowest price it dropped to was $10.14. The 52-week range on FOLD shows that it touched its highest point at $12.63 and its lowest point at $5.91 during that stretch. It currently has a 1-year price target of $14.22. Beta for the stock currently stands at 1.00.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of FOLD was down-trending over the past week, with a drop of -2.45%, but this was down by -5.73% over a month. Three-month performance surged to 48.57% while six-month performance rose 9.62%. The stock gained 11.15% in the past year, while it has lost -10.22% so far this year. A look at the trailing 12-month EPS for FOLD yields -0.97 with Next year EPS estimates of -0.14. For the next quarter, that number is -0.22. This implies an EPS growth rate of 13.70% for this year and 83.00% for next year.

Float and Shares Shorts:

At present, 288.48 million FOLD shares are outstanding with a float of 250.84 million shares on hand for trading. On Jul 14, 2022, short shares totaled 21.75 million, which was 7.76% higher than short shares on Jun 14, 2022. In addition to Mr. John F. Crowley as the firm’s Chairman & CEO, Mr. Bradley L. Campbell M.B.A. serves as its Pres, COO & Director.

Institutional Ownership:

Through their ownership of 111.76% of FOLD’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 62.80% of FOLD, in contrast to 45.19% held by mutual funds. Shares owned by individuals account for 23.82%. As the largest shareholder in FOLD with 9.84% of the stake, Perceptive Advisors LLC holds 27,555,845 shares worth 27,555,845. A second-largest stockholder of FOLD, Wellington Management Co. LLP, holds 26,619,107 shares, controlling over 9.50% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in FOLD, holding 24,986,323 shares or 8.92% stake. With a 3.09% stake in FOLD, the SPDR S&P Biotech ETF is the largest stakeholder. A total of 8,645,122 shares are owned by the mutual fund manager. The Vanguard Total Stock Market Index, which owns about 2.95% of FOLD stock, is the second-largest Mutual Fund holder. It holds 8,264,428 shares valued at 88.76 million. Vanguard Small Cap Index Fund holds 2.52% of the stake in FOLD, owning 7,067,673 shares worth 75.91 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for FOLD since 12 analysts follow the stock currently. There are 8 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 4 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With FOLD analysts setting a high price target of $20.00 and a low target of $10.00, the average target price over the next 12 months is $14.50. Based on these targets, FOLD could surge 92.86% to reach the target high and fall by -3.57% to reach the target low. Reaching the average price target will result in a growth of 39.83% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. FOLD will report FY 2022 earnings on 02/23/2023. Analysts have provided yearly estimates in a range of -$0.58 being high and -$1.01 being low. For FOLD, this leads to a yearly average estimate of -$0.85. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Amicus Therapeutics Inc. surprised analysts by -$0.05 when it reported -$0.30 EPS against a consensus estimate of -$0.25. The surprise factor in the prior quarter was -$0.13. Based on analyst estimates, the high estimate for the next quarter is -$0.15 and the low estimate is -$0.29. The average estimate for the next quarter is thus -$0.21.

Summary of Insider Activity:

Insiders traded FOLD stock several times over the past three months with 8 Buys and 9 Sells. In these transactions, 97,906 shares were bought while 102,840 shares were sold. The number of buy transactions has increased to 43 while that of sell transactions has risen to 61 over the past year. The total number of shares bought during that period was 1,405,692 while 886,704 shares were sold.

Leave a Comment

Your email address will not be published.